Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed (confirmed by tissue testing) with primary CNS lymphoma, diffuse large B cell lymphoma that has spread to the brain, B cell non-Hodgkin's lymphoma confirmed by fluid testing, or ocular (eye) lymphoma with measurable tumour in the brain
• People whose cancer has grown during or after first-line treatment, did not respond well enough to previous treatment, came back after initially responding, or who could not tolerate previous treatment due to serious side effects such as kidney injury or liver problems
• People whose physical condition meets a minimum fitness threshold on a standard medical scale (for people under 60, a score of at least 30%; for people aged 60 or older, a score of at least 50%)
• People whose cancer is confined to the brain and/or eyes, with no lymphoma detected elsewhere in the body on recent scans
• People whose blood counts, liver function, and kidney function meet the minimum levels required by the trial
• People who are able to sign informed consent, or whose consent can be provided by a proxy if they have cognitive or physical difficulties caused by their condition
• People with a life expectancy of at least 2 months
• Women of childbearing potential who test negative for pregnancy within 7 days before starting treatment and who agree to use highly effective contraception during the trial and for at least 30 days after the last dose
• Male participants with female partners of childbearing potential who agree to use appropriate contraception during treatment and for up to one week after the last dose
• People living with HIV, provided their viral load is undetectable and their CD4 count is above 400
• People with a history of Hepatitis C, provided the virus is not currently detectable in the blood
• People who have a positive Hepatitis B core antibody but a negative Hepatitis B surface antigen result

Who may not be able to join:

• People with serious uncontrolled illnesses or other significant medical conditions alongside their cancer
• People with another active cancer, except for certain low-risk skin cancers, early-stage cervical changes, or very low-risk prostate cancer being monitored without treatment (people with a cancer history of 3 or more years ago with no current active disease may still be considered)
• People currently receiving other immune therapies or targeted therapies not included in this trial
• People who are unlikely to be able to follow the study requirements
• People who have received chemotherapy, immunotherapy, radiation, or other cancer treatments within the 2 weeks before starting the trial
• People who are pregnant or breastfeeding
• People whose liver enzyme levels are more than 3 times the normal upper limit
• People who have a pre-existing condition that suppresses the immune system, or who are currently on immune-suppressing medications (with limited exceptions for low-dose steroids for chronic conditions)
• People who have received an organ transplant from another person (donor), or who have had a stem cell transplant from a donor; people who had their own stem cell transplant may be considered if their cancer returned more than one year after that transplant
• People with active autoimmune conditions causing destruction of their own blood cells or platelets
• People with wounds, ulcers, or bone fractures that are not healing
• People with known bleeding disorders such as von Willebrand's disease or haemophilia
• People who have had a stroke or bleeding in the brain within the past 6 months, or a blood clot in a vein or artery (such as a deep vein thrombosis or pulmonary embolism) within the past 3 months
• People currently taking warfarin or similar blood-thinning medications (these would need to be stopped at least 7 days before starting the trial)
• People living with HIV who have a detectable viral load or a CD4 count below 400
• People with detectable Hepatitis B surface antigen in their blood
• People with significant active heart conditions, including a heart attack within the past 6 months, unstable chest pain within the past 3 months, severe heart failure, or a history of serious heart rhythm problems
• People with an active infection requiring treatment that was completed 7 days or fewer before the start of the trial
• People taking certain medications that strongly interact with a liver enzyme called CYP3A, which can affect how the trial drugs work
• People with any condition that, in the treating doctor's judgement, could make participation unsafe
• People who have previously been treated with pemetrexed or a type of drug called a BTK inhibitor for lymphoma
• People who have received a live or weakened-virus vaccine within 28 days before starting treatment (live vaccines are also not permitted during treatment)
• People with a known allergy or hypersensitivity to zanubrutinib, pemetrexed, or any of their ingredients

Important: Always verify eligibility with the trial site directly before applying.